All News

Whether patients present with complaints of an aching muscle from a workout or a sudden twinge in the back, consider recommending these topical analgesics.

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

In case you missed it, this week we had stories about the availability of the first liquid nonstimulant for ADHD, pharmacy technicians as "vaccine champions," SGLT2i's heart-healthy benefits, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.

Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.

Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.

Senators Ron Wyden and Sherrod Brown wrote a letter to the Federal Trade Commission calling to explore yet another PBM tactic impeding competition.

See what’s trending in pharmacy with a preview of the Drug Topics September/October issue.

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

The Heart Failure Society of America 2024 Annual Meeting featured presentations exploring the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for patients with heart failure.

Investigators compared semaglutide and other glucagon-like peptide-1 receptor agonists with dipeptidyl peptidase-4 inhibitors.

Several posters presented at the Heart Failure Society of America 2024 Annual Meeting looked into the landscape of guideline-directed medical therapy.

In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.

Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Lea Wolsoncroft of Remedies Pharmacy in Hoover, Alabama, discussed what is going on in her pharmacy practice.

Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.

Vaccination against respiratory viruses such as RSV and the flu are crucial to prevent adverse outcomes in patients with heart failure.

Left ventricular ejection fraction, brain natriuretic peptide, and heart failure-related hospitalizations were among the improved metrics.

Sara T. Thomason discuses the impact of stigma on pharmacists who are dealing with substance use disorder, the importance of mental health care, and how schools support pharmacy students dealing with addiction.